Business
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT Additional Presentations at ASGCT Showcase Tenaya’s Work with Patients to Advance Gene Therapy and Early-Stage Pipeline Innovations in Cardiac Gene Editing SOUTH SAN FRANCISCO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curat
About this update from Tenaya Therapeutics, Inc.
[{"type":"image","alt":"Tenaya Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Tenaya Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aaM78VHLlwFUIjp7XWFupw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6","width":300,"height":108}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:100%;width:100%;min-width:100%;text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":"Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT","length":133,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":"Additional Presentations at ASGCT Showcase Tenaya’s Work with Patients to Advance Gene Therapy and Early-Stage Pipeline Innovations in Cardiac Gene Editing","length":155,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]}],"length":294},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the acceptance of multiple abstracts for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026, in Boston, Massachusetts. Of note, new clinical data from both dose cohorts of the RIDGE-1 Phase 1b/2 trial of TN-401 will be featured as a late-breaking oral presentation.","length":622,"tagName":"p"},{"type":"text","co...